That is essential, due to the fact that the way a protein in the body folds figures out if a pharmaceutical will be able to bind to that protein and be reliable. To put it simply, we have to understand how these proteins fold if we want a drug to work. Historically, this has been a trial-and-error procedure (jeff brown top biotech stock 2021). Now, Alpha, Fold can forecast protein folding with 92. 4% precision. That's going to make it much simpler to create drugs that do what they're designed to do. This was an advancement almost nobody discovered. However it's going to have extensive implications for treating illness. I anticipate that Alpha, Fold will be 98% accurate by the end of 2021.
And, naturally, there will be plenty of financial investment opportunities in this space, too. Shifting subjects It's going to be a good year for bitcoin. I'm bullish on it in 2021 (future report). That stated, I still think bitcoin will continue to be unpredictable. We're close to all-time highs. I would not be amazed if it pulled back perhaps considerably prior to going higher - legacy report prediction. I have actually been covering bitcoin for a long period of time now. One of the first research study reports I ever released was on bitcoin. That was in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $34,000 today.
However at the time of that initial suggestion, I titled my report "What's the Big Offer With Bitcoin?" That reveals you where the discussion was at the time. We were primarily educating readers. But that's not the huge question any longer. Now we're seeing institutional cash lastly take an interest in bitcoin. Massachusetts Mutual Life Insurance took a $100 million stake in bitcoin in December. This is not some small, niche business. Mass, Mutual is a relied on 170-year-old institution. So consider that. In 5 years, we went from educating readers on what bitcoin is to a company like Mass, Mutual taking a $100 million stake.
And that's a huge factor I'm bullish on it this year. future report review. Regards, Jeff Brown, Editor, The Bleeding Edge I have a bonus forecast 2020 was a record year for IPOs. 552 U.S. companies went public the most in more than 20 years. These business raised an overall of $172 billion. That's an all-time high beating the previous yearly record by 43%. I anticipate 2021 will be another record year in IPOs. There are so numerous terrific private companies on the brink of hitting the public markets And I have actually been dealing with a new method for you to invest even before these companies go public.
This opportunity has actually been developing over the last few years. I can't wait to inform you everything about it. Join me tomorrow at 8 p. m. ET for my Pre-IPO Code Event to discover all the details. Go right here to schedule your spot for complimentary.
Emma Walsh here, handling editor of the Diary. Regular Journal readers know that tech isn't our typical beat (jeff brown top biotech 2020). And when it pertains to tech investing, we leave it to the experts. Luckily, we have a number of such specialists in our Rolodex. Our coworker Jeff Brown will recognize to our longtime readers. He is one of the most accomplished tech investing professionals we understand (jeff brown stock market prediction). In fact, he had several triple-digit returns in his Brownstone Research portfolios last year. Here's what Jeff believes the tech sector will bring us in 2021 Each year, I like to take a look at the big picture and forecast what's just around the corner.
That includes things like 5G networks, biotech, artificial intelligence, and far more. These patterns are experiencing rapid growth and creating amazing opportunities for financiers. I wish to make certain all our readers are gotten ready for what's next. And with that in mind, let me draw the photo of what I see coming in the next 12 months Our new 5G (fifth-generation) wireless networks are a subject I have actually been covering for years now. bleeding edge. But despite what lots of readers may think, this is a pattern that's simply beginning. Although the COVID-19 pandemic disrupted supply chains last year, an excellent 250 million 5G-enabled devices were still offered.
And all of this eventually led to Apple delaying the release of the 5G-enabled i, Phone 12 by 2 months (legacy report prediction). Losing two months of manufacturing and sales really affects how numerous 5G devices are offered in the fiscal year. When you think about all of that, offering 250 million units is remarkable. More notably, the hold-ups triggered by the pandemic developed a lots of pent-up demand. Which demand is now going to be pushed into 2021. In truth, I anticipate that more than 500 million 5G gadgets will be shipped in 2021 - first lady. Which's not my only 5G forecast When I have actually discussed 5G in the past, I have actually explained its three different phases.
In Phase Two, 5G devices go on sale. 5G phones and other items start to reach customers. And in Phase Three, 5G services start to be offered (artificial intelligence). That's when we begin to see applications running on 5G networks. Think about things like enormous multiplayer games over a smart phone. That's not possible with 4G. It will be with 5G. And my second 5G prediction for 2021 is that we will start Phase Three by this summertime. This begins something of a virtuous cycle: Many people do not really appreciate the technology. However they will care if there are interesting applications that can only be accessed with a 5G phone.
That causes more 5G apps being established. In truth, 5G is going to open up a suite of extraordinary applications: self-driving cars and trucks, the Internet of Things, robotic surgical treatment, and more. All of these technologies require 5G. The investment opportunities moving forward will be enormous. Stepping away from 5G, the next essential innovation I anticipate in 2021 is CRISPR genetic editing. CRISPR represents "clustered routinely interspaced short palindromic repeat." It's a mouthful. But it's one of the most amazing advancements in biotechnology. At a high level, CRISPR is a technology that can edit our genetic makeup as if it were software.
The program can crash or not operate properly. CRISPR utilizes a comparable concept however with our genetic code. "Typos" in our genome can lead to disease. CRISPR can fix these "typos." For years, CRISPR was mostly a specific niche technology that wasn't well comprehended. And throughout that time, there were truly only three companies operating in this area. However things are altering. CRISPR is no longer just theoretical. We're seeing actual results. We're treating illness and seeing that this technology just works. And as an outcome, a "2nd crop" of early-stage CRISPR business is going public and delivering amazing returns. This whole market is successfully a greenfield chance.
There's space for many business to exist in this area. genetic sequencing companies jeff brown. And there will be more. That's my forecast for CRISPR in 2021. I forecast that 2 or three more genetic modifying business will hold their IPOs. Sticking with biotechnology, we are seeing incredible things taking place at the merging of biotech and expert system (AI). Google's AI subsidiary, Deep, Mind, just announced at the end of 2020 that its latest Alpha, Fold software can accurately anticipate the folding of a protein based solely on its amino acid series with 92. 4% accuracy. That is necessary since the way a protein in the body folds figures out if a pharmaceutical will be able to bind to that protein and be reliable.
Historically, this has actually been a trial-and-error procedure. And now, Alpha, Fold can anticipate protein folding with 92. 4% precision. That's going to make it a lot easier to produce drugs that do what they're created to do. And here's my next prediction. I anticipate that Alpha, Fold will be 98% accurate by the end of 2021. And we will see not just one but a number of drug treatments produced using this technology. This was one of those advancements that almost no one discovered. But it's going to have extensive ramifications for curing disease. And, naturally, there will be plenty of investment opportunities in this space, too.
It's going to be a great year for bitcoin. I'm bullish on it in 2021. That stated, I still think bitcoin will continue to be unpredictable. We're close to all-time highs. I wouldn't be surprised if it drew back maybe considerably before going higher. I've been covering bitcoin for a long time now. Among the first research study reports I ever released was on bitcoin - jeff brown biotech stocks. That was in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $40,000 today. So that's a 16,500%+ return on financial investment for anybody who followed my suggestion. But at the time of that preliminary suggestion, I entitled my report, "What's the Big Deal With Bitcoin?" That reveals you where the discussion was at the time.
But no one is asking that question anymore. Now, we're seeing institutional money finally taking an interest in bitcoin. The big news was that Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some small, niche business. jeff brown 1 biotech. Mass, Mutual is a 150-year-old organization. So think of that. In five years, we went from informing readers on what bitcoin is to a business like Mass, Mutual taking a $100 million stake. The institutional adoption of bitcoin will continue. Which's a huge reason why I'm bullish on it this year. Regards, Jeff Brown, Editor, The Bleeding Edge I have one more bonus offer prediction In 2021, we're going to have another record year in IPOs. One website reports that Jeff Brown deserves about $27. 5 million and claims the information depends on date as of February 2021, but we might not independently validate this claim. Provided Jeff Brown's past, he likely has a substantial net worth, but we can't hammer down a precise figure at this minute. Brown is best understood for his sage-like ability to select winning technology stocks. He invested more than 25 years researching innovation companies like Qualcomm, NXP semiconductors, and Juniper Networks. Brown's comprehensive experience provides him an outstanding point of view on the marketplace. He's constantly on the hunt for brand-new chances, and he shares a lot of his best picks in the Near Future Report.
That's full marks, but it's not ridiculously reasoned. Brown has an outstanding credibility as a stock-picker, and he effectively forecasted some of the greatest economic events of the previous twenty years. Although he does not appear to release his picks to the general public, the service's success is a direct indicator of Brown's stock-picking prowess. Nobody on Wall Street gets it right every time, but Jeff Brown's precise forecasts have earned him legions of dedicated followers. That says a lot about his capability. The Near Future Report is released by Brownstone Research study, a prominent monetary research publisher. Brownstone Research offers a number of research services with a wide range of specializations - brownstone research stock.
The company is also affiliated with Bonner & Partners, another well-respected research publisher - jeff brown biotech picks. On its website, Brownstone states its mission is to supply retail investors with professional-grade research study: "For too long, the very best financial investment research has not been offered to private investors. It has actually been usually reserved for investment banks, hedge funds, private equity, and high-net-worth customers. jeff brown prediction. The mission of Brownstone Research study is to make that kind of exclusive research available to any financiers aiming to gain an edge in the marketplaces. The objective is simple to provide unique and successful financial investment research discovered nowhere else." -Brownstone Research study website excerpt from the Jeff Brown is the creator of Brownstone Research, and he also acts as the company's Chief Financial investment Expert.
With Brown assisting the ship, Brownstone Research study is a powerhouse publisher with lots to use its customers. After years of steady success at the helm of top-tier business like Tesla and Space, X, Elon Musk is a household name throughout the majority of America. If you understand even a bit about the marketplace, you understand that he has a track record as a King Midas of sorts. biotech stocks. Everything he touches turns to gold! Jeff is aware of Elon Musk's executive prowess, so he constantly has an eye out for the Silicon Valley rock star's next relocation. This time, Jeff has an early lead on Elon's next huge job.
In reality, Brown believes S.A.V. jeff brown top biotech stock 2021. could be "the greatest trend of the 2020s, and he's not alone. Take a look at these quotes from other well-known S.A.V. bulls: Elon's next big act will be weding two cutting-edge technologies: expert system and electrical vehicles. Musk hopes the combination will assist him develop the first fully-autonomous, self-driving automobiles ever. It's nothing short of the vehicle market's Holy Grail. As you know, electric vehicles and self-driving cars and truck stocks have actually been substantial this year, however the Wall Street device has been huge on buzz without much tangible outcome. Despite an extreme increase in competitors over the previous couple of years, Brown still thinks Musk has the finest possibility of putting it all together.
tech could be the magic string that ties it all together. S.A.V. represents Shared Autonomous Automobile, and it might be the future of transport. Generally, this innovation would allow you to rent out your cars and truck as a self-governing, self-driving taxi when you're not using it. You simply leave the vehicle and press a button on an app that informs the cars and truck to "join the fleet." Next thing you know, you're unwinding on your sofa while your vehicle shuttles ride-sharers around town. Best of all, you get to keep a hefty chunk of the profits. It sounds crazy, but it could be closed than you think.